(LEGN) Legend Biotech Corporation Porters Five Forces Research

Legend Biotech Corporation faces high supplier power because critical inputs for cell therapy often have no easy substitute. Switching materials can trigger comparability studies, new filings, and long regulatory reviews, so even small changes carry time and risk.

That is a real constraint for a 2025 business that generated about $1.0 billion in CARVYKTI sales, where supply continuity matters more than price cuts.

• Few substitute inputs exist
• Switching needs regulatory review
• Supplier leverage stays elevated

Legend Biotech Corporation’s Janssen tie-up helps blunt supplier pressure by widening scale and giving access to J&J’s development, manufacturing, and commercialization base. CARVYKTI passed $1 billion in 2024 sales, so the partnership clearly has leverage. Still, supplier power stays moderate to high because cell therapy inputs are specialized and hard to replace.

• CARVYKTI sales topped $1 billion in 2024.
• Dependence stays concentrated with Janssen.
• Specialized capacity keeps supplier power elevated.

As myeloma and lymphoma options expand, buyers can compare Legend Biotech Corporation’s CAR-T drugs with bispecific antibodies like teclistamab and elranatamab, ADCs like polatuzumab vedotin, and standard triplets used across relapsed disease. With several approved choices in the same lines of therapy, providers and payers gain more switching leverage. That keeps customer power moderate to high.

• More approved rivals raise choice.
• Bispecifics and ADCs cut switching costs.
• Payers can push price and access terms.

Buyers still demand strong response, long durability, safety, and easy logistics before they switch. In mature U.S. markets, Legend Biotech Corporation’s CARVYKTI faces sharp scrutiny because advanced cell therapy can cost over $400,000 per infusion, so payers and hospitals want solid post-launch proof, not just trial data.

• High price lifts buyer bargaining power.
• Real-world durability data matters most.
• Safety and site logistics affect adoption.

That matters more as the base grows: CARVYKTI sales topped $963 million in 2024, so each new account can push hard on evidence and terms.

Legend Biotech Corporation faces strong rivalry because its hematology pipeline sits in crowded lanes like CD19, CD20, CD22, and BCMA, where multiple rivals chase the same biology. In 2024, CARVYKTI net trade sales reached about $1.0 billion, but as more programs move from early data to late-stage readouts, head-to-head pressure and target overlap can make share gains harder.

• CD19, CD20, CD22, BCMA overlap
• More late-stage readouts, more rivalry
• Same targets raise redundancy risk

Legend Biotech Corporation faces strong pricing pressure because CAR-T and other oncology drugs can cost about $400,000 to $500,000 per treatment, so buyers focus on net price, not just outcomes. Payers and hospitals often demand rebates, bundled terms, or outcomes-based contracts, which raises competitive rivalry and can squeeze gross margin. This matters even more as more high-cost cell therapies enter the market and buyers compare total cost of care.

• Net price drives buying decisions.
• Payers push discounts and rebates.
• Hospitals want bundled terms.
• Outcome-based deals shift risk.

Antibody-drug conjugates, checkpoint combos, and newer targeted drugs keep widening Legend Biotech Corporation's substitute risk, especially in myeloma and other hematology settings. CAR-T still needs complex cell collection and weeks-long vein-to-vein time, while many ADCs and small-molecule options are off-the-shelf, so community oncology practices may favor them. That gives buyers easier alternatives and can cap pricing power.

• Off-the-shelf therapies are simpler to use.
• Community clinics may prefer lower-logistics options.
• Substitutes pressure CAR-T demand and pricing.

Emerging cell and gene therapies are a moderate-to-high substitute threat for Legend Biotech Corporation, because rivals are advancing autologous, allogeneic, and engineered immune-cell platforms that target similar cancers. If they deliver lower cost, faster production, or better persistence, they can pull demand away from Legend Biotech Corporation’s current CAR-T platform. The threat should rise as these next-wave therapies move closer to scale.

• Same disease areas
• Lower cost and faster scale
• Better persistence raises risk

Legend Biotech Corporation operates in a patent-heavy CAR-T field, so new entrants must clear rights on constructs, targets, manufacturing steps, and clinical uses. That pushes entry costs up because firms often need licenses or face injunction and damages risk. In 2025, CARVYKTI remained a major flagship product, and that kind of IP moat still favors incumbents.

• Licensing can be mandatory.
• Patent risk lifts entry costs.
• IP shields incumbents in CAR-T.

Hospitals, oncologists, and payers already prefer therapies with proven outcomes, support programs, and dependable supply, so a newcomer must build trust and reimbursement access from zero. In 2025, CARVYKTI remained one of only a few approved BCMA CAR-T options, which shows how hard it is to break established clinical and payer ties. That keeps new-entrant risk low, even in a scientifically attractive market.

• Trust takes years to build
• Reimbursement access is hard
• Supply reliability matters
• Few approved BCMA rivals